Non-invasive Diagnostic for Assessing Elevated Intracranial Pressure
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Rosina Samadani, PhD
- Phone Number: (917) 302-4333
- Email: rosina@oculogica.com
Study Contact Backup
- Name: Viridiana Juarez
- Phone Number: 484-393-2694
- Email: viridiana@oculogica.com
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins Hospital
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Provide written informed consent.
- Require placement of an ICP monitor or ventriculostomy catheter for clinical purposes.
- Be between the ages of 4 and 70 years old.
- Have baseline vision correctable to within 20/500 bilaterally.
- Have no prior history of ocular dysmotility.
- Be awake with spontaneous eye opening at the time when eye tracking is performed.
Exclusion Criteria:
- Have a prior history of strabismus, diplopia, or palsy of CN-III, IV or VI.
- Be blind (no light perception), have missing eyes, be unable to open their eyes.
- Have a prior history of ocular motility dysfunction.
- Have had extensive prior eye surgery.
- Have any physical or mental injury or baseline disability rendering task completion difficult.
- Be intoxicated or have blood alcohol level greater than 0.2.
- Be a prisoner or in the company of a police officer or law enforcement officer pending arrest.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
single
subjects with abnormal intracranial pressure
|
non-invasive ICP Score algorithm using eye-tracking data from the EyeBOX(TM) device, which tracks the movement of the pupils over time
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sensitivity and Specificity
Time Frame: from time of enrollment through the period that ICP monitoring is required for clinical purposes up to 104 weeks
|
EyeBOX assessment of abnormal ICP relative to invasive intracranial pressure monitor
|
from time of enrollment through the period that ICP monitoring is required for clinical purposes up to 104 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Eric Jackson, MD, Johns Hopkins University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ICP001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intracranial Pressure Increase
-
NCT03640741CompletedLaparoscopy | Increase in Intra-abdominal Pressure | Increase in Intracranial Pressure (ICP) | Cerebral Perfusion and Oxygenation
-
NCT06403592RecruitingIntracranial Pressure Increase
-
NCT05731765Active, not recruitingIntracranial Pressure Increase
-
NCT05609071Active, not recruitingBrain Diseases | Intracranial Pressure Increase
-
NCT04004923CompletedIntracranial Pressure Increase
-
NCT05931991Recruiting
-
NCT04046523RecruitingIntracranial Pressure Increase
-
NCT06048900CompletedIntracranial Pressure Increase
-
NCT05668208CompletedIntracranial Pressure Increase
-
NCT04758091CompletedIntracranial Pressure Increase
Clinical Trials on EyeBOX for ICP
-
NCT04799093CompletedImpairment | Cannabis Intoxication
-
NCT05527041Enrolling by invitationMild Traumatic Brain Injury | Concussion, Brain
-
NCT03966404CompletedMild Traumatic Brain Injury | Concussion, Brain
-
NCT02776462CompletedBrain Injuries | Craniocerebral Trauma | Trauma, Nervous System | Brain Concussion | Concussion, Mild | Concussion, Severe | Concussion, Intermediate | Cerebral Concussion
-
NCT05728658RecruitingHematological Malignancies
-
NCT05702268RecruitingModerate to Severe Atopic Dermatitis
-
NCT05047003CompletedMild Traumatic Brain Injury | Concussion, Brain
-
NCT06842199RecruitingPlaque Psoriasis Patients
-
NCT07440537Not yet recruitingCutaneous Lupus Erythematosus (CLE)
-
NCT06109818CompletedModerate to Severe Plaque Psoriasis